Table 2. Safety Analyses of Study Subjects at Baseline and After 4 Weeks.
| TRC150094 (N = 20) | Placebo (N = 20) | |||
| Baseline | Week 4 | Baseline | Week 4 | |
| Systolic blood pressure, mm Hg | 140±8 | 140±9 | 137±10 | 133±9 |
| Diastolic blood pressure, mm Hg | 88±4 | 88±5 | 87±7 | 85±8 |
| Pulse, beats/min | 76±10 | 74±9 | 87±7 | 75±7 |
| Body temperature, °C | 36.6±0.5 | 36.4±0.5 | 36.6±0.4 | 36.4±0.4 |
| Body weight, kg | 101±18 | 103±21 | 103±19 | 102±15 |
| Liver function | ||||
| ALT, U/L | 40±22 | 39±20 | 34±10 | 34±15 |
| AST, U/L | 29±12 | 27±11 | 29±13 | 26±9 |
| GGT, IU/L | 44±31 | 43±28 | 46±31 | 47±34 |
| Thyroid function | ||||
| FT3, pmol/L | 4.27±1.02 | 4.88±1.29 | 4.45±0.68 | 5.11±1.03 |
| FT4, pmol/L | 11.70±2.12 | 12.57±1.96* | 12.1±1.84 | 12.3±1.94 |
| TSH, mIU/L | 2.10±0.00 | 2.23±1.14 | 1.86±0.67 | 2.01±1.06 |
NOTE. Values are expressed as mean ± standard deviation.
*Nonparametric test showed a significant increase in FT4 after TRC150094 (p = 0.025). ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyltransferase; FT3, free trio-iodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone (thyrotropin).